Lilly CEO Discusses Growth Beyond Weight Loss Drugs

Lilly has become one of the world's most valuable companies due to the popularity of its GLP-1 treatments, Mounjaro and Zepbound. The company's stock has increased 10-fold since 2018, surpassing rivals like Novo Nordisk and exceeding the market capitalization of ExxonMobil or JPMorgan Chase.

This growth has benefited employees and local businesses in Indianapolis. Dave Ricks, who has led Lilly since 2017, emphasized the need to focus on advancing current offerings and finding new innovations. He noted that GLP-1 drugs currently reach only about one in 10 eligible people in the U.S., where 40% of health spending addresses obesity-related issues.

Ricks stated that significant growth potential remains.

The FDA recently approved Lilly's GLP-1 pill, Foundayo, which Ricks said could reduce daily friction for users by fitting into pill routines, unlike injectables. He highlighted its potential for scalable production to reach more of the estimated 500 million potential global customers, compared to the current 21 or 22 million treated.

Additionally, the pill could serve as a maintenance option after weight loss goals are met. Lilly announced the acquisition of Centessa Pharmaceuticals, focusing on sleep disorders. Ricks described sleep as a key health condition that could improve outcomes in aging, dementia, mental health, and conditions like ADD and ADHD.

He noted Lilly's history in neuroscience positions it well for this exploration.

This week, Lilly agreed to spend up to $7 billion to acquire Kelonia Therapeutics, developing a treatment for multiple myeloma. Ricks mentioned that smaller biotech companies face disadvantages in U.S. tariff and most favored nation deals but have not become cheaper.